Following 8 successful years, the Immunogenicity and Bioassay Summit is expanding to include SIX short courses, TWO training seminars, AND a one-day immersive symposium in addition to our THREE conference tracks. These events provide an invaluable opportunity to learn how the experts manage the challenges of Immunogenicity Assessment, Prediction and Risk Mitigation, as well as Bioanalytical and Bioassay Development.  Once again, attendees will hear from the regulatory authorities and be able to discuss their challenges with them. NEW this year is a focus on Bioassays for Immuno-Oncology, Immunology for Scientists in Biotherapeutic Discovery and Development, and an Introduction to Design of Experiments. The 2017 summit features:

• 250+ Global Attendees
• 75 Scientific Presentations & Case Studies, including FDA
• Exhibit & Poster Hall
• Track-hopping allowed for concurrent conferences
• Panel Discussions

Viswanath Devanarayan, Ph.D.

Adjunct Professor

University of Illinois at Chicago

Susan Kirshner, Ph.D.

Associate Chief, Immunology Lab, Therapeutic Proteins, Biotechnology

FDA/CDER

Thomas Little, Ph.D.

President, Bioassay Sciences

Thomas A. Little Consulting

Sofie Pattijn

Chief Technology Officer

ImmunXperts

Joao Pedras-Vasconcelos, Ph.D.

Biotech Quality and Immunogenicity Reviewer, Biotechnology Products

CDER-FDA

Amy S. Rosenberg, M.D.

Division Director, Office of Biotechnology Products

FDA/CDER

Perceval Sondag

Senior Statistician, Non-Clinical Statistics

Arlenda

“This conference provides very deep and broad scientific presentations, roundtable discussions, and excellent networking opportunities for scientists, managers/directors, CROs, vendors and consultants.”
- Senior Group Leader, Pfizer

“The Immunogenicity and Bioassay Summit covers up-to-date research and regulatory advances on all aspects of immunogenicity. It’s a very good meeting for experts and newcomers to the field.”
- Senior Director, Head, Bioanalytical and Biomarker Development, Research & Nonclinical Development, Shire

“Program and participants first class.”
- Associate Director, Novo Nordisk

“Great to get regulatory perspectives on challenges and expectations. The higher level strategic discussions were very informative.”
- Beth Arnold, Director, Biologics & Vaccine Bioanalytics, Merck

“Breakout interaction with FDA experts was very valuable.”
- Associate Director, Alexion Pharmaceuticals Inc.

View more testimonials